Dr Reddy Laboratories, Srikakulam Plant (SEZ) has received zero observations, in an audit conducted by the US Food and Drug Administration.
Last week, the FDA conducted an audit at its active pharmaceutical ingredient (API) Srikakulam special economic zone (SEZ) plant, and has reported zero observations. The API SEZ plant is a fully automated new generation plant serving the US market.
Further, the facility is used for filing new products and is also designated for transferring manufacturing of certain existing products.
